Boston, MA -- (SBWIRE) -- 07/14/2012 -- The non-small cell lung cancer pipeline is growing as a result of an increased understanding of the disease's heterogeneity, which has led to the development of personalized therapies targeting distinct patient subtypes. The success of these personalized therapies is likely to incentivize pharmaceutical companies to continue developing targeted therapies for niche patient populations.
- Analysis of marketed NSCLC drugs - development history, key clinical trial data, and assessment of clinical and commercial attractiveness
- Analysis of marketed drugs in comparison to current standard of care
- In-depth analysis of late-stage pipeline drugs - development overview, SWOT analysis, and assessment of clinical and commercial attractiveness
- Discussion and assessment of pipeline drugs' ability to meet unmet needs in treatment of non-small cell lung cancer
View Full Report Details and Table of Contents
Pipeline drugs such as Bristol-Myers Squibb's Erbitux (cetuximab) and Roche's MetMab (onartuzumab) are currently being trialed in combination with platinum chemotherapy and Avastin respectively. Roche will inevitably benefit if MetMab is approved in this setting given Avastin's already established physician familiarity and high uptake.
Targeted therapies maintain competition for greater market share. Avastin remains dominant, particularly in the US, but Tarceva (erlotinib), Iressa (gefitinib) and Xalkori (crizotinib) will increase pressure on Avastin given that their use in specific patient subsets avoids exposing unsuitable patients to unnecessary side-effects.
Targeted and immunotherapeutic drugs dominate the late-stage pipeline. Lucanix (belagenpumatucel-L) and Stimuvax (BLP-25) are the most advanced immunotherapies in the pipeline, looking set to enter the market in the second-line and maintenance settings respectively. No immunotherapies are currently approved for non-small cell lung cancer
Reasons to Get this Report
- Understand the dynamics of non-small cell lung cancer therapy and identify the market leaders in this competitive indication.
- Compare and assess current late-stage pipeline drugs according to market positioning, commercial potential and clinical efficacy.
- Understand how pipeline drugs will be used with current therapies and how the market is accessed through less competitive treatment settings.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Small-Cell Lung Cancer - Pipeline Review, H1 2012
- Small-Cell Lung Cancer - Pipeline Review, Q3 2011
- Non-Small Cell Lung Cancer - Pipeline Review, H2 2011
- Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2012
- Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2012
- Non-Small Cell Lung Cancer - Pipeline Review, H1 2012
- Cell Therapeutics, Inc. (CTIC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
- Transitional Cell Cancer - Pipeline Review, Q2 2011
- OSI Pharmaceuticals, Inc. (OSIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile